Company
Virion Therapeutics
T cell-based Immunotherapies for Cancer and Infectious Diseases
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2018
Claim, correct or request removal
Record updated 28 September 2026
About
Virion Therapeutics is a clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize proprietary checkpoint modifiers to restore, enhance, broaden, and elicit sustained immune responses, with the goal to cure cancer and chronic infectious diseases.
Funding snapshot
- Total raised
- $5MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Undisclosed, $5M2018-09-16
Funding rounds
- Round, 2018
- $5M2018-09-16, Company stated
Products
- Other
- VRON-0200
- Other
- VRON-0300
Loading relationship preview